Amedisys Reports Second Quarter Financial Results

Amedisys Reports Second Quarter Financial Results

Amedisys to Host Conference Call Today at 10:00 a.m. ET

BATON ROUGE, La., July 30, 2014 (GLOBE NEWSWIRE) -- Amedisys, Inc.
(Nasdaq:AMED), a leading home health and hospice company, today reported its
financial results for the three and six-month periods ended June 30, 2014.

Three-Month Periods Ended June 30, 2014 and 2013

  *After adding back for the 2014 period, $0.8 million ($0.5 million, net of
    income tax ) or $0.02 per diluted share and for the 2013 period $6.1
    million ($3.8 million, net of income tax) or $0.12 per diluted share for
    certain items*, our adjusted results from continuing operations were as
    follows:

       *Net service revenue of $305.0 million compared to $316.0 million in
         2013.
       *Net income from continuing operations attributable to Amedisys, Inc.
         of $8.0 million compared to net income from continuing operations of
         $5.8 million in 2013. (Net income from continuing operations
         attributable to Amedisys, Inc. of $7.6 million compared to net income
         from continuing operations attributable to Amedisys, Inc. of $2.0
         million in 2013 on a GAAP basis.)
       *Net income from continuing operations attributable to Amedisys, Inc.
         per diluted share of $0.25 compared to net income from continuing
         operations attributable to Amedisys, Inc. of $0.18 per diluted share
         in 2013. (Net income from continuing operations attributable to
         Amedisys, Inc. per diluted share $0.23 compared to net income from
         continuing operations attributable to Amedisys Inc. per diluted share
         of $0.06 per diluted share in 2013 on a GAAP basis.)
       *Earnings before interest, taxes, depreciation and amortization
         attributable to continuing operations ("EBITDA") of $22.1 million
         compared to $19.6 million in 2013.

Six-Month Periods Ended June 30, 2014 and 2013

  *After adding back for the 2014 period, $16.9 million ($10.4 million, net
    of income tax ) or $0.32 per diluted share and for the 2013 period $8.2
    million ($5.0 million, net of income tax) or $0.16 per diluted share for
    certain items*, our adjusted results from continuing operations were as
    follows:

       *Net service revenue of $603.7 million compared to $644.6 million in
         2013.
       *Net income from continuing operations attributable to Amedisys, Inc.
         of $5.8 million compared to net income from continuing operations of
         $10.4 million in 2013. (Net loss from continuing operations
         attributable to Amedisys, Inc. of $4.6 million compared to net income
         from continuing operations attributable to Amedisys, Inc. of $5.4
         million in 2013 on a GAAP basis.)
       *Net income from continuing operations attributable to Amedisys, Inc.
         per diluted share of $0.18 compared to net income from continuing
         operations attributable to Amedisys, Inc. of $0.33 per diluted share
         in 2013. (Net loss from continuing operations attributable to
         Amedisys, Inc. per diluted share $0.14 compared to net income from
         continuing operations attributable to Amedisys Inc. per diluted share
         of $0.17 per diluted share in 2013 on a GAAP basis.)
       *EBITDA of $27.6 million compared to $37.9 million in 2013.

Ronald A. LaBorde, Interim Chief Executive Officer stated, "While much work
remains, our progress in this quarter reflects the focus of our entire
Amedisys team. We believe we have reestablished a solid foundation which will
allow us to concentrate on further improving our core business."

We urge caution in considering the current trends disclosed in this press
release. The home health and hospice industry is highly competitive and
subject to intensive regulations, and trends are subject to numerous factors,
risks, and uncertainties, some of which are referenced in the cautionary
language below and others that are described more fully in our reports filed
with the Securities and Exchange Commission ("SEC") including our Annual
Report on Form 10-K for the fiscal year ended December 31, 2013, and
subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K
which can be found on the SEC's internet website, http://www.sec.gov, and our
internet website, http://www.amedisys.com. We disclaim any obligations to
update disclosed information on trends.

* See the Reconciliation of Non-GAAP Financial Measures to GAAP Financial
Statements table below for explanation of these certain items and the
reconciliations of non-GAAP financial measures.

Earnings Call and Webcast Information

To participate in the conference call, please call a few minutes before 10:00
a.m. ET on Wednesday, July 30, 2014, to either (877) 512-9171 (Toll free) or
(815) 573-0979 (Toll), use conference ID #77505164. A replay of the conference
call will be available through August 30, 2014. The replay dial in number is
(855) 859-2056 (Toll free) or (404) 537-3406 (Toll), use conference ID
#77505164.

The call will also be available through our website and for seven days
thereafter at the following web address: http://investors.amedisys.com.

We are headquartered in Baton Rouge, Louisiana. Our common stock trades on the
NASDAQ Global Select Market under the symbol "AMED."

Additional information

Our company website address is www.amedisys.com. We use our website as a
channel of distribution for important company information. Important
information, including press releases, analyst presentations and financial
information regarding our company, is routinely posted on and accessible on
the Investor Relations subpage of our website, which is accessible by clicking
on the tab labeled "Investors" on our website home page. We also use our
website to expedite public access to time-critical information regarding our
company in advance of or in lieu of distributing a press release or a filing
with the SEC disclosing the same information. Therefore, investors should look
to the Investor Relations subpage of our website for important and
time-critical information. Visitors to our website can also register to
receive automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations subpage of our
website.

Forward-Looking Statements

When included in this press release, words like "believes," "belief,"
"expects," "plans," "anticipates," "intends," "projects," "estimates," "may,"
"might," "would," "should" and similar expressions are intended to identify
forward-looking statements as defined by the Private Securities Litigation
Reform Act of 1995. These forward-looking statements involve a variety of
risks and uncertainties that could cause actual results to differ materially
from those described therein. These risks and uncertainties include, but are
not limited to the following: changes in Medicare and other medical payment
levels, our ability to open care centers, acquire additional care centers and
integrate and operate these care centers effectively, changes in or our
failure to comply with existing Federal and State laws or regulations or the
inability to comply with new government regulations on a timely basis,
competition in the home health industry, changes in the case mix of patients
and payment methodologies, changes in estimates and judgments associated with
critical accounting policies, our ability to maintain or establish new patient
referral sources, our ability to attract and retain qualified personnel,
changes in payments and covered services due to the economic downturn and
deficit spending by Federal and State governments, future cost containment
initiatives undertaken by third-party payors, our access to financing due to
the volatility and disruption of the capital and credit markets, our ability
to meet debt service requirements and comply with covenants in debt
agreements, business disruptions due to natural disasters or acts of
terrorism, our ability to integrate and manage our information systems, our
ability to fund required settlement payments in the manner agreed upon in our
settlement agreement to resolve both the U.S. Department of Justice
investigation and the Stark Law Self-Referral matter, our ability to comply
with requirements stipulated in our corporate integrity agreement and changes
in law or developments with respect to any litigation or investigations
relating the Company, including the OIG Self-Disclosure issues and various
other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified, you should not
rely on any forward-looking statement as a prediction of future events. We
expressly disclaim any obligation or undertaking and we do not intend to
release publicly any updates or changes in our expectations concerning the
forward-looking statements or any changes in events, conditions or
circumstances upon which any forward-looking statement may be based, except as
required by law.

Non-GAAP Financial Measures

This press release includes the following non-GAAP financial measures as
defined under SEC rules: EBITDA, defined as net income (loss) from continuing
operations attributable to Amedisys, Inc. before provision for income taxes,
net interest expense and depreciation and amortization, adjusted EBITDA,
defined as EBITDA excluding certain other items, adjusted net income (loss)
from continuing operations attributable to Amedisys, Inc., defined as net
income (loss) from continuing operations attributable to Amedisys, Inc.
excluding certain other items, and adjusted net income (loss) from continuing
operations attributable to Amedisys, Inc. per diluted share, defined as net
income (loss) from continuing operations attributable to Amedisys, Inc. common
stockholders per diluted share excluding certain other items. In accordance
with SEC rules, we have provided herein a reconciliation of these non-GAAP
financial measures to the most directly comparable measures under GAAP.
Management believes that these are useful gauges of our performance and are
common measures used in our industry to assess relative financial performance
among companies.

                                                           
AMEDISYS, INC. AND SUBSIDIARIES
SELECT CONSOLIDATED FINANCIAL STATEMENT DATA AND SUPPLEMENTAL INFORMATION
(Amounts in thousands, except share, per share data and statistical
information)
(Unaudited)
                                                           
Balance Sheet Information
                                              June30,2014 December31,2013
ASSETS                                                      
Current assets:                                             
Cash and cash equivalents                     $11,225      $17,303
Patient accounts receivable, net of allowance  110,934      111,133
for doubtful accounts of $14,956 and $14,231
Prepaid expenses                               10,855       10,669
Deferred income taxes                         10,712       55,329
Other current assets                          15,185       10,785
Assets held for sale                          —           60
                                                           
Total current assets                          158,911      205,279
                                                           
Property and equipment, net of accumulated     148,346      159,025
depreciation of $140,705 and $129,89
                                                           
Goodwill                                       205,587      208,915
Intangible assets, net of accumulated          34,112       36,690
amortization of $25,354 and $25,133
Deferred income taxes                         134,442      90,214
Other assets, net                             28,898       26,283
                                                           
Total assets                                  $710,296     $726,406
                                                           
LIABILITIES AND EQUITY                                      
Current Liabilities:                                        
Accounts payable                              $18,886      $20,139
Accrued charge related to U.S. Department of   35,000       150,000
Justice settlement
Payroll and employee benefits                 72,861       70,801
Accrued expenses                              61,712       57,572
Current portion of long-term obligations      12,277       13,904
                                                           
Total current liabilities                     200,736      312,416
Long-term obligations, less current portion   132,000      33,000
Other long-term obligations                   6,518        8,511
                                                           
Total liabilities                             339,254      353,927
                                                           
Equity:                                                     
Preferred stock, $0.001 par value, 5,000,000   —           —
shares authorized; none issued or outstanding
                                                           
Common stock, $0.001 par value, 60,000,000
shares authorized; 34,153,969 and 33,413,970   34           33
shares issued; and 33,195,927 and 32,538,971
shares outstanding
Additional paid-in capital                    473,634      467,890
Treasury stock at cost, 958,042 and 874,999    (19,464)     (18,176)
shares of common stock
Accumulated other comprehensive income        15           15
Retained earnings                             (82,359)     (77,561)
                                                           
Total Amedisys, Inc. stockholders' equity     371,860      372,201
Noncontrolling interests                      (818)        278
                                                           
Total equity                                  371,042      372,479
                                                           
Total liabilities and equity                   $710,296     $726,406

                                      

                                                               
Statement of Operations Information
                                                   
                        FortheThree-MonthPeriods FortheSix-MonthPeriods
                         Ended June30,              Ended June30,
                        2014          2013          2014          2013
Net service revenue     $305,006    $315,960    $603,745     $644,562
Cost of service,
excluding depreciation   172,520     177,760     349,527      363,427
and amortization
General and                                                     
administrative expenses:
Salaries and benefits   71,400      75,012      154,571      154,852
Non-cash compensation   1,069       1,224       1,500        3,280
Other                   35,522      41,378      78,222       83,226
Provision for doubtful   4,242       4,639       9,135        8,493
accounts
Depreciation and         7,692       9,411       15,594       19,381
amortization
Other intangibles        —          2,286       2,208        2,286
impairment charge
                                                               
Operating expenses      292,445     311,710     610,757      634,945
                                                               
Operating income (loss) 12,561      4,250       (7,012 )     9,617
Other income (expense):                                         
Interest income         16          11          22           22
Interest expense        (1,352)      (714)        (2,613)      (1,806)
Equity in earnings from  885         337         1,671        700
equity investments
Miscellaneous, net      243         (537)        434          (478)
                                                               
Total other expense,     (208)        (903)        (486)        (1,562)
net
                                                               
Income (loss) before     12,353      3,347       (7,498 )     8,055
income taxes
Income tax (expense)     (4,743)      (1,342)      2,875        (3,193)
benefit
                                                               
Income (loss) from       7,610       2,005       (4,623 )     4,862
continuing operations
Discontinued operations, 61          (157)       (216)        (882)
net of tax
                                                               
Net income (loss)        7,671       1,848       (4,839 )     3,980
Net (income) loss
attributable to          (52)         (7)         41           539
noncontrolling
interests
                                                               
Net income (loss)
attributable to          $7,619      $1,841      $(4,798)     $4,519
Amedisys, Inc.
                                                               
Basic earnings per                                              
common share:
Income (loss) from
continuing operations
attributable to          $0.24       $0.06       $(0.14)      $0.18
Amedisys, Inc. common
stockholders
                                                               
Discontinued operations, —          —          (0.01)       (0.03)
net of tax
                                                               
Net income (loss)
attributable to          $0.24       $0.06       $(0.15)      $0.15
Amedisys, Inc. common
stockholders
                                                               
Weighted average shares  32,251      31,160      32,058       30,900
outstanding
                                                               
Diluted earnings per                                            
common share:
Income (loss) from
continuing operations
attributable to          $0.23       $0.06       $(0.14)      $0.17
Amedisys, Inc. common
stockholders
                                                               
Discontinued operations, —          —          (0.01)       (0.03)
net of tax
                                                               
Net income (loss)
attributable to          $0.23       $0.06       $(0.15)      $0.14
Amedisys, Inc. common
stockholders
                                                               
Weighted average shares  32,594      31,489      32,058       31,298
outstanding
                                                               
Amounts attributable to
Amedisys, Inc. common                                           
stockholders:
Income (loss) from       $7,558      $1,998      $(4,582 )    $5,401
continuing operations
Discontinued operations, 61          (157)        (216)        (882)
net of tax
                                                               
Net income (loss)        $7,619      $1,841      $(4,798)     $4,519
                                                               

                                      

Cash Flow and Days Revenue Outstanding, Net Information
                                                
                  FortheThree-MonthPeriods    FortheSix-MonthPeriods
                   Ended June30,                 Ended June30,
                  2014            2013           2014           2013
                                                             
Net cash (used in)
provided by        $(89,129)      $33,561      $(95,471)     $65,977
operating
activities
Net cash used in
investing          (4,472)        (7,390)       (9,392)       (24,215)
activities
Net cash provided
by (used in)       101,986       (3,074)       98,785        (26,189)
financing
activities
                                                             
Net increase
(decrease) in cash 8,385         23,097       (6,078)       15,573
and cash
equivalents
Cash and cash
equivalents at     2,840         7,021        17,303        14,545
beginning of
period
                                                             
Cash and cash
equivalents at end $11,225       $30,118      $11,225       $30,118
of period
                                                             
Days revenue
outstanding, net   32.0          33.9         32.0          33.9
(1)
                                                             
(1)Our calculation of days revenue outstanding, net at June30, 2014 and 2013
is derived by dividing our ending patient accounts receivable (i.e., net of
estimated revenue adjustments and allowance for doubtful accounts) by our
average daily net patient revenue for the three month-period ended June30,
2014 and 2013, respectively.

                                      

                                                          
Supplemental Information - Home Health
                                               
                                               For the Three-Month
                                                Periods Ended June30,
                                               2014        2013
Financial Information (in millions):                       
Medicare                                       $191.5     $204.6
Non-Medicare                                   52.0       45.9
Net service revenue                            243.5      250.5
                                                          
Cost of service                                139.3      143.2
                                                          
Gross margin                                   104.2      107.3
Other operating expenses                       73.2       81.7
                                                          
Operating income before impairment charges (1) $31.0      $25.6
                                                          
Key Statistical Data:                                      
Medicare:                                                  
Same Store Volume (2):                                     
Revenue                                        2%         (10%)
Admissions                                     0%         0%
Recertifications                               2%         (18%)
Total (3):                                                 
Admissions                                     43,974     47,734
Recertifications                               26,283     27,493
Completed episodes                             70,276     75,461
Visits                                         1,225,278   1,323,138
Average revenue per completed episode (4)      $2,845     $2,831
Visits per completed episode (5)               17.5       17.7
                                                          
Non-Medicare (3):                                          
Admissions                                     20,731     18,235
Recertifications                               8,057      7,532
Visits                                         412,481    380,502
                                                          
Total (3):                                                 
Cost per Visit                                 $85.08     $84.09
Visits                                         1,637,759   1,703,640

                                      

                                                           
                                         For the Six-Month Periods
                                          Ended June30,
                                         2014               2013
Financial Information (in millions):                        
Medicare                                 $380.2            $417.2
Non-Medicare                             100.0             95.3
                                                           
Net service revenue                      480.2             512.5
Cost of service                          283.3             293.7
                                                           
Gross margin                             196.9             218.8
Other operating expenses                 155.8             166.4
                                                           
Operating income before impairment        $41.1             $52.4
charges (1)
                                                           
Key Statistical Data:                                       
Medicare:                                                   
Same Store Volume (2):                                      
Revenue                                  (2%)              (9%)
Admissions                               (1%)              1%
Recertifications                         (2%)              (18%)
Total (3):                                                  
Admissions                               90,501            97,741
Recertifications                         52,061            56,180
Completed episodes                       137,748           151,345
Visits                                   2,429,817         2,694,022
Average revenue per completed episode     $2,812            $2,804
(4)
Visits per completed episode (5)         17.2              17.6
                                                           
Non-Medicare (3):                                           
Admissions                               41,924            39,821
Recertifications                         15,508            15,732
Visits                                   802,621           802,858
                                                           
Total (3):                                                  
Cost per Visit                           $87.65            $83.99
Visits                                   3,232,438         3,496,880
                                                           
(1)Operating income of $23.3 million on a GAAP basis for the three-month
period ended June30, 2013. Operating income of $39.9 million and $50.1
million on a GAAP basis for the six-month periods ended June30, 2014 and
2013, respectively.
(2)Medicare revenue, admissions or recertifications same store volume is the
percent increase (decrease) in our Medicare revenue, admissions or
recertifications for the period as a percent of the Medicare revenue,
admissions or recertifications of the prior period.
(3) Based on continuing operations for all periods presented.
(4)Average Medicare revenue per completed episode is the average Medicare
revenue earned for each Medicare completed episode of care which excludes the
impact of sequestration.
(5)Medicare visits per completed episode are the home health Medicare visits
on completed episodes divided by the home health Medicare episodes completed
during the period.

                                      

                                                    
Supplemental Information - Hospice
                                       
                                       FortheThree-MonthPeriods
                                        Ended June30,
                                       2014          2013
Financial Information (in millions):                 
Medicare revenue                       $57.7       $61.6
Non-Medicare revenue                   3.8         3.8
                                                    
Net service revenue                    61.5        65.4
Cost of service                        33.2        34.5
                                                    
Gross margin                           28.3        30.9
Other operating expenses               15.2        18.0
                                                    
Operating income                       $13.1       $12.9
                                                    
Key Statistical Data:                                
Same store Medicare revenue growth (2) (3%)         (12%)
Hospice admits                         4,350       4,655
Average daily census                   4,649       5,006
Revenue per day                         $145.44     $143.61
Cost of service per day                $78.24      $75.34
Average length of stay                 99          99

                                      

                                                        
                                   FortheSix-MonthPeriods
                                    Ended June30,
                                   2014                  2013
Financial Information (in                                
millions):
Medicare revenue                   $116.1               $124.4
Non-Medicare revenue               7.4                  7.6
                                                        
Net service revenue                123.5                132.0
Cost of service                    66.2                 69.7
                                                        
Gross margin                       57.3                 62.3
Other operating expenses           32.8                 37.8
                                                        
Operating income before impairment  $24.5                $24.5
charges (1)
                                                        
Key Statistical Data:                                    
Same store Medicare revenue growth  (4%)                 (8%)
(2)
Hospice admits                     8,945                9,612
Average daily census               4,685                5,038
Revenue per day                     $ 145.70              $ 144.79
Cost of service per day            $77.86               $76.19
Average length of stay             99                   101
                                                        
(1) Operating income of $23.5 million on a GAAP basis for the six-month period
ended June30, 2014.
(2) Same store Medicare revenue volume is the percent increase (decrease) in
our Medicare revenue for the period as a percent of the Medicare revenue of
the prior period.

                                      

                                                 
Supplemental Information - Corporate
                                    
                                    FortheThree-MonthPeriods
                                     Ended June30,
                                    2014          2013
Financial Information (in millions):              
Other operating expenses            $26.7        $25.8
Depreciation and amortization       4.8          6.2
                                                 
Total                               $31.5        $32.0

                                      

                                                
                                    FortheSix-MonthPeriods
                                     Ended June30,
                                    2014         2013
Financial Information (in millions):             
Other operating expenses            $60.8      $52.1
Depreciation and amortization       9.6        12.9
                                                
Total                               $70.4      $65.0
                                                

                                      

                                                              
AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP FINANCIAL STATEMENTS
(Amounts in thousands)
(Unaudited)
                                                   
Earnings From Continuing Operations Before Interest, Taxes, Depreciation and
Amortization ("EBITDA") and Adjusted EBITDA
                                                   
                        FortheThree-MonthPeriods FortheSix-MonthPeriods
                         Ended June30,            Ended June30,
                        2014          2013          2014         2013
Net income (loss)
attributable to          $7,619      $1,841      $(4,798)    $4,519
Amedisys, Inc.
Less:                                                          
Discontinued operations, 61          (157)        (216)       (882)
net of tax
                                                              
Net income (loss) from
continuing operations    7,558       1,998       (4,582)     5,401
attributable to
Amedisys, Inc.
Add:                                                           
Provision for income     4,743       1,342       (2,875)     3,193
taxes
Interest expense, net   1,336       703         2,591      1,784
Depreciation and         7,692       9,411       15,594     19,381
amortization
                                                              
EBITDA (1)              21,329      13,454      10,728     29,759
Add:                                                           
Certain items (2)       784         6,133       16,884     8,164
                                                              
Adjusted EBITDA (3)     $22,113     $19,587     $27,612    $37,923

                                      

                                                              
Adjusted Net Income (Loss) From Continuing Operations Attributable to
Amedisys, Inc. Reconciliation:
                                                   
                        FortheThree-MonthPeriods FortheSix-MonthPeriods
                         Ended June30,              Ended June30,
                        2014          2013          2014         2013
Net income (loss)
attributable to          $7,619      $1,841      $(4,798)    $4,519
Amedisys, Inc.
Less:                                                          
Discontinued Operations, 61          (157)        (216)       (882)
net of tax
                                                              
Net income (loss) from
continuing operations    7,558       1,998       (4,582)     5,401
attributable to
Amedisys, Inc.
Add:                                                           
Certain items (2)       482         3,777       10,400     5,028
                                                              
Adjusted net income
(loss) from continuing   $8,040      $5,775      $5,818     $10,429
operations attributable
to Amedisys, Inc.(4)
                                                              

                                      

                                                             
Adjusted Net Income (Loss) From Continuing Operations Attributable to
Amedisys, Inc. per Diluted Share:
                                                
                  FortheThree-MonthPeriods    FortheSix-MonthPeriods
                   Ended June30,               Ended June30,
                  2014            2013           2014           2013
Net income (loss)
attributable to
Amedisys, Inc.     $0.23         $0.06        $(0.15)       $0.14
common
stockholders per
diluted share
Less:                                                         
Discontinued
operations, net of —            —           (0.01)        (0.03)
tax
                                                             
Net income (loss)
from continuing
operations
attributable to    0.23          0.06         (0.14)        0.17
Amedisys, Inc.
common
stockholders per
diluted share
Add:                                                          
Certain items (2) 0.02          0.12         0.32         0.16
                                                             
Adjusted net
income (loss) from
continuing
operations
attributable to    $0.25         $0.18        $0.18        $0.33
Amedisys, Inc.
common
stockholders per
diluted share (5)
                                                             
(1)EBITDA is defined as net income (loss) from continuing operations
attributable to Amedisys, Inc. before provision for income taxes, net interest
expense, and depreciation and amortization. EBITDA should not be considered as
an alternative to, or more meaningful than, income before income taxes, cash
flow from operating activities, or other traditional indicators of operating
performance. This calculation of EBITDA may not be comparable to a similarly
titled measure reported by other companies, since not all companies calculate
this non-GAAP financial measure in the same manner.
(2)The following details the certain other items for the three and six-month
periods ended June30, 2014 and 2013:

                                      

                                                                
                   For the Three-Month Period     For the Six-Month Period
                    Ended June30, 2014          Ended June30, 2014
                   (Income)   Net       Diluted   (Income)  Net      Diluted
                    Expense              EPS       Expense          EPS
Other intangibles   $—       $—      $—      $2,208   $1,360  $0.04
impairment charge
Exit and
restructuring       —        —       —       9,954    6,132   0.19
activity costs
Relator fees       —        —       —       3,938    2,426   0.07
OIG                 1,450     893      0.03     1,450    893     0.03
self-disclosure
Software write-off 1,465     902      0.03     1,465    902     0.03
Gain on sale of     (2,131)   (1,313)  (0.04)   (2,131)  (1,313) (0.04)
care centers
                                                                
Total              $784      $482     $0.02    $ 16,884  $ 10,400 $0.32
                                                                
                                                 
                   For the Three-Month Period     For the Six-Month Period
                    Ended June30, 2013            Ended June30, 2013
                   (Income)   Net       Diluted   (Income)  Net      Diluted
                    Expense              EPS       Expense            EPS
Other intangibles   $2,286    $1,408   $0.05    $2,286   $1,408  $0.05
impairment charge
Exit and
restructuring       1,569     966      0.03     1,569    966     0.03
activity costs
Relator fees       —        —       —       —       —      —
Legal fees         1,606     989      0.03     3,637    2,240   0.07
Loss on sale of     672       414      0.01     672      414     0.01
care centers
                                                                
Total              $6,133    $3,777   $0.12    $8,164   $5,028  $0.16
                                                                
(3)Adjusted EBITDA is defined as net income (loss) from continuing operations
attributable to Amedisys, Inc. before provision for income taxes, net interest
expense, depreciation and amortization excluding certain other items as
described in footnote 2. Adjusted EBITDA should not be considered as an
alternative to, or more meaningful than, income before income taxes, cash flow
from operating activities, or other traditional indicators of operating
performance. This calculation of adjusted EBITDA may not be comparable to a
similarly titled measure reported by other companies, since not all companies
calculate this non-GAAP financial measure in the same manner.
(4)Adjusted net income (loss) from continuing operations attributable to
Amedisys, Inc. is defined as net income (loss) from continuing operations
attributable to Amedisys, Inc. excluding certain other items as described in
footnote 2. Adjusted net income (loss) from continuing operations attributable
to Amedisys, Inc. should not be considered as an alternative to, or more
meaningful than, income before income taxes, cash flow from operating
activities, or other traditional indicators of operating performance. This
calculation of adjusted net income (loss) from continuing operations
attributable to Amedisys, Inc. may not be comparable to a similarly titled
measure reported by other companies, since not all companies calculate this
non-GAAP measure in the same manner.
(5)Adjusted net income (loss) from continuing operations attributable to
Amedisys, Inc. common stockholders per diluted share is defined as diluted
income (loss) from continuing operations per share excluding the earnings per
share effect of certain other items as described in footnote 2. Adjusted net
income (loss) from continuing operations attributable to Amedisys, Inc. common
stockholders per diluted share should not be considered as an alternative to,
or more meaningful than, income before income taxes, cash flow from operating
activities, or other traditional indicators or operating performance. This
calculation of adjusted net income (loss) from continuing operations
attributable to Amedisys, Inc. common stockholders per diluted share may not
be comparable to a similarly titled measure reported by other companies, since
not all companies calculate this non-GAAP financial measure in the same
manner.

CONTACT:
         Investor Contact:
         Amedisys, Inc.
         David Castille
         Director, Treasury/Finance
         (225) 299-3391
         david.castille@amedisys.com
        
         Media Contact:
         Amedisys, Inc.
         Kendra Kimmons
         Managing Director, Marketing & Communications
         (225) 299-3720
         kendra.kimmons@amedisys.com

Amedisys, Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.